Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Double Blind Prospective, Non Comparative Proof of Concept Phase II Study
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Anifrolumab (Primary)
- Indications Vitiligo
- Focus Proof of concept; Therapeutic Use
- Acronyms VITANI
- 18 Dec 2023 Planned End Date changed from 1 Dec 2025 to 1 May 2026.
- 18 Dec 2023 Planned primary completion date changed from 1 Dec 2025 to 1 May 2026.
- 18 Dec 2023 Status changed from not yet recruiting to recruiting.